Minimally Invasive Treatment of Lung Cancer Market Report 2026

The minimally invasive treatment of lung cancer market size has grown strongly in recent years. It will grow from $3.35 billion in 2025 to $3.67 billion in 2026 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to increasing lung cancer incidence rates, expansion of oncology treatment centers, improvements in interventional radiology techniques, rising availability of minimally invasive treatment options, growing clinical acceptance of ablation therapies.

The minimally invasive treatment of lung cancer market size is expected to see strong growth in the next few years. It will grow to $5.21 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to increasing investments in precision cancer care, rising adoption of robotic and AI-assisted oncology treatments, expansion of early-stage lung cancer detection programs, growing demand for outpatient cancer procedures, increasing focus on personalized treatment pathways. Major trends in the forecast period include increasing adoption of image-guided tumor ablation techniques, rising use of minimally invasive embolization procedures, growing integration of robotic assistance in oncology care, expansion of precision oncology treatment platforms, enhanced focus on reduced treatment-related complications.

The rising prevalence of lung cancer is expected to drive the growth of the minimally invasive treatment of lung cancer market in the coming years. Lung cancer, a type of cancer originating in the lungs, is characterized by uncontrolled cell growth. Its increasing incidence is largely linked to tobacco smoking, which elevates the risk of abnormal cell proliferation and tumor development. Minimally invasive treatments assist lung cancer patients by targeting and removing or destroying tumors through small incisions or imaging-guided probes, which shortens recovery time, limits damage to healthy lung tissue, reduces complication risks, and allows patients to resume normal activities more quickly. For example, in January 2023, according to a report by the American Cancer Society, a U.S.-based non-profit organization, approximately 238,340 individuals - 117,550 men and 120,790 women - were expected to be diagnosed with lung cancer in 2023, with an estimated 127,070 deaths resulting from the disease. Consequently, the increasing prevalence of lung cancer is contributing to the expansion of the minimally invasive treatment market.

Leading companies in the minimally invasive lung cancer treatment market are focusing on developing innovative technologies, such as microwave ablation systems and navigation-assisted biopsy platforms, to address the growing demand for lung-sparing therapies, faster diagnosis, shorter hospital stays, and treatment options for patients ineligible for open surgery. Microwave ablation (MWA) devices deliver high-frequency electromagnetic energy through a probe to rapidly heat and coagulate tumor tissue, creating predictable spherical ablation zones with faster treatment times and reduced heat-sink effects compared to radiofrequency ablation. For instance, in January 2025, Creo Medical Group plc, a UK-based medical device company specializing in minimally invasive surgical endoscopy, introduced the MicroBlate Flex soft-tissue microwave ablation system and initiated clinical studies for lung lesions. The MicroBlate Flex system consists of a microwave generator and flexible ablation applicator designed for multiple soft-tissue indications. It operates by emitting high-frequency microwave energy at the applicator tip to create controlled thermal zones that destroy tumor cells. Its features include an efficient high-frequency power profile, flexible delivery for hard-to-reach anatomies, and compatibility with endoscopic or percutaneous approaches, making it suitable for small pulmonary nodules, metastatic lung lesions, and patients who cannot tolerate lobectomy. Clinically, this enables shorter procedure times, reduced need for general anesthesia, potential outpatient workflows, and a broader range of treatment options compared with open surgery or stereotactic radiotherapy.

In February 2025, Toulouse University Hospital, a France-based medical institution, acquired Epione from Quantum Surgical for an undisclosed amount. Through this acquisition, Toulouse University Hospital aims to enhance its minimally invasive, robot-assisted treatment capabilities for abdominal and lung tumors, enabling physicians to perform highly precise procedures, improve patient outcomes, reduce recovery times, and expand access to advanced oncological care in the Occitanie region. Quantum Surgical, a France-based medical technology company, specializes in minimally invasive solutions for small and hard-to-reach lung tumors.

Major companies operating in the minimally invasive treatment of lung cancer market are Johnson & Johnson, Medtronic plc, Siemens Healthineers AG, Stryker Corporation, Boston Scientific Corporation, Olympus Corporation, Intuitive Surgical Inc., Accuray Incorporated, Richard Wolf GmbH, AngioDynamics Inc., CMR Surgical Ltd., Guangzhou Geyi Medical Instrument Co. Ltd., Quantum Surgical SA, Scanlan International Inc., RZ Medizintechnik GmbH & Co. KG, August Reuchlen GmbH, SBH Surgical GmbH & Co. KG, Geister Medizintechnik GmbH, Cook Medical Incorporated, Terumo Corporation, Merit Medical Systems Inc., Sirtex Medical Limited.

North America was the largest region in the minimally invasive treatment of lung cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the minimally invasive treatment of lung cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the minimally invasive treatment of lung cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the minimally invasive treatment of lung cancer market by increasing costs of imported ablation devices, embolization materials, imaging systems, robotic platforms, and specialized catheters. Cancer treatment centers in North America and Europe are most affected due to reliance on imported high-precision equipment, while Asia-Pacific faces higher procurement costs for advanced oncology technologies. These tariffs are increasing procedure costs and slowing technology upgrades. However, they are also driving domestic device manufacturing, regional innovation in interventional oncology tools, and development of cost-efficient minimally invasive treatment solutions.

The minimally invasive treatment of lung cancer market research report is one of a series of new reports that provides minimally invasive treatment of lung cancer market statistics, including minimally invasive treatment of lung cancer industry global market size, regional shares, competitors with a minimally invasive treatment of lung cancer market share, detailed minimally invasive treatment of lung cancer market segments, market trends and opportunities, and any further data you may need to thrive in the minimally invasive treatment of lung cancer industry. This minimally invasive treatment of lung cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Minimally invasive lung cancer treatment uses small incisions and advanced techniques, such as video-assisted or robotic surgery, to target or remove lung tumors while minimizing damage to surrounding tissues. This approach is designed to accelerate recovery, reduce complications, and improve patient outcomes compared to traditional open surgery.

The primary types of minimally invasive lung cancer treatment include lung tumor ablation and lung tumor embolization. Lung tumor ablation destroys cancer cells by applying extreme heat or cold directly to the tumor using imaging-guided probes. These treatments are applicable across various stages of lung cancer, including stages I, II, III, and IV, and for patients in different age groups, such as under 30 years, 31-45 years, and 46-60 years. They are utilized by a range of end-users, including hospitals, ambulatory surgical centers (ASCs), specialty clinics, and research institutions.

The minimally invasive treatment of lung cancer market consists of revenues earned by entities by providing services such as diagnostic imaging, bronchoscopic procedures, chemotherapy delivery, targeted therapy administration and postoperative care. The market value includes the value of related goods sold by the service provider or included within the service offering. The minimally invasive treatment of lung cancer market also includes of sales of implants, catheters, endoscopes, navigation systems and imaging systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.